Clearmind Medicine Inc., a clinical-stage biotech company, has announced the expansion of its ongoing Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD) with the inclusion of Tel Aviv Sourasky Medical Center in Israel. The trial is evaluating CMND-100, a proprietary MEAI-based oral drug candidate. The enrollment of the first patient was completed earlier this month. The study at Tel Aviv Sourasky Medical Center will be led by Dr. David Zeltser. This expansion includes other prestigious institutions such as Yale School of Medicine and Johns Hopkins University School of Medicine. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while exploring its potential to reduce alcohol cravings and consumption in patients with AUD. Results from the trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.